Sign In
Buy XBI
$129.83
+2.07 (+1.62%)
At Close: Jun 03, 2026
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
07:32am, Friday, 23'rd Sep 2022
Smart Beta ETF report for XBI
Life sciences is undervalued right now, says JMP Securities Mark Lehmann
05:17pm, Monday, 19'th Sep 2022
JMP Securities CEO Mark Lehmann joins 'Closing Bell: Overtime' to discuss why he likes health care stocks as the place to be right now.
Has the Market Bottomed? Low P/E ETFs to Bounce Back
09:02am, Friday, 16'th Sep 2022
According to Ari Wald, head of technical analysis at Oppenheimer, we're on the verge of a turnaround right now, as quoted on TipRanks, published on Yahoo Finance.
Here's who could benefit from Biden's biotech initiative, according to Oppenheimer's Jared Holz
06:30pm, Monday, 12'th Sep 2022
Oppenheimer's Jared Holz on President Biden's cancer initiative and what it means for biotech in the U.S. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Courtney Garcia, Guy Adami an
XBI: Risk/Reward Still Favorable
04:07pm, Monday, 12'th Sep 2022
The XBI ETF gives investors a low-cost and convenient way to gain exposure to the biotech sector. The ETF is modified equal weighted, so no single company dominates.
The Key to Profitable Trades in This Market
08:58pm, Thursday, 08'th Sep 2022
A media giant to add to your watchlist
Buy the recent dip in Biotech stocks: Jefferies
01:55pm, Monday, 05'th Sep 2022
“XBI” – the SPDR S&P Biotech ETF down more than 10% over the past three weeks is an opportunity to “buy”, says Michael Yee. He's a Managing Director at Jefferies.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
07:32am, Monday, 05'th Sep 2022
Sector ETF report for XBI
SBIO Was ALPS' Top Performing ETF in August
01:55pm, Thursday, 01'st Sep 2022
The ALPS Medical Breakthroughs ETF (SBIO) was ALPS' top-performing ETF in August, propelled by positive earnings and M&A announcements in the portfolio. SBIO increased 8.65% on a total return basi
Why Now Could Be The Time To Consider Neuroscience Investments
04:45am, Saturday, 27'th Aug 2022
Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomic
What The Inflation Reduction Act Means For Drug Prices
01:24am, Friday, 26'th Aug 2022
The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry's long-term financial performance. The legislation caps out-of-pocket costs
Biotech ETFs Are on the Mend
06:03pm, Friday, 19'th Aug 2022
Biotechnology sector-related exchange traded funds are making a swift rebound as a spate of dealing making and new drug approvals helped reinvigorate the segment. For instance, the SPDR S&P Biotech ET
Biotech Rebounds on Optimism and Deal Making
05:30am, Friday, 19'th Aug 2022
The sector had tumbled in the market selloff, but it is getting a boost from big investors and big pharmaceutical companies.
How Are Biotech ETFs Reacting to Q2 Earnings Releases?
09:02am, Thursday, 18'th Aug 2022
he Biotech sector has been in a sweet spot for quite some time now. Plus, earnings releases have also come in mostly upbeat.
Hedge fund says there are 2 areas in the U.S. in which it has 'aggressive positions'
04:40am, Tuesday, 16'th Aug 2022
Thomas Hayes of Great Hill Capital explains why it's positive on U.S. biotech and auto suppliers.
